Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: Results from a 12-month, comparative, phase III study

BJU International

Volumn 106, Issue 2, 2010, Pages 182-187

  Schröder, Fritz H ^a   Tombal, Bertrand ^b   Miller, Kurt ^c   Boccon Gibod, Laurent ^d   Shore, Neal D ^e   Crawford, E David ^f   Moul, Judd ^g   Olesen, Tine Kold ^h   Persson, Bo Eric ⁱ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d BICHAT HOSPITAL   (France)

^e Carolina Urologic Research Center   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h Ferring Pharmaceuticals Inc USA   (United States)

ⁱ Ferring Pharmaceuticals AS   (Denmark)

Author keywords

alkaline phosphatase; degarelix; disease stage; leuprolide; prostate cancer; prostate specific antigen

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; DEGARELIX; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; EPIDEMIOLOGIC METHODS; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77953849770     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08981.x     Document Type: Article

References (30)

1. Conti G, La TG, Cicalese V et al. Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. Arch Ital Urol Androl 2008 80 : 59 64
2. Schwartz GG. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 2008 17 : 478 483
3. Jung K, Lein M, Von Stephan CHK et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004 111 : 783 791
4. Morote J, Lorente JA, Encabo G. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Cancer 1996 78 : 2374 2378 (Pubitemid 26392838)
5. Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001 88 : 226 230
6. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000 88 (Suppl. 2952 2960
7. Pouessel D, Gallet B, Bibeau F et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int 2007 99 : 807 811
8. Pelger RC, Lycklama ANG, Zwinderman AH, Papapoulos SE, Hamdy NA. The flare in serum alkaline phosphatase activity after orchiectomy: a valuable negative prognostic index for progression-free survival in prostatic carcinoma. J Urol 1996 156 : 122 126
9. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993 77 : 1046 1053
10. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996 155 : 1348 1351 (Pubitemid 26081236)
11. Lein M, Wirth M, Miller K et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007 52 : 1381 1387
12. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007 67 : 330 340
13. Johansen JS, Brasso K, Iversen P et al. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 2007 13 : 3244 3249
14. Robinson D, Sandblom G, Johansson R et al. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 2008 179 : 117 122
15. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005 7 (Suppl. 5 S3 12
16. Van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008 71 : 1001 1006
17. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991 265 : 618 621
18. Vogelzang NJ, Chodak GW, Soloway MS et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 1995 46 : 220 226
19. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000 86 : 449 452
20. Ryan CW, Huo D, Bylow K et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007 100 : 70 5
21. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008 102 : 1531 1538
22. Kreis W, Ahmann FR, Lesser M et al. Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Oncol 1990 8 : 870 874
23. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA 2006 103 : 14925 14930
24. European Medicines Agency. Assessment Report for Firmagon (Doc. Ref: EMEA/CHMP/635761/2008). 2008. Accessed 28 April 2009
25. Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008 113 : 193 201
26. Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005 97 : 59 69
27. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005 23 : 4925 4935
28. Stock RG, Stone NN. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 1997 13 : 454 460
29. D'Amico AV, Chen MH, Catalona WJ et al. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 2007 110 : 56 61
30. Tombal B, Miller K, Boccon-Gibod L et al. Degarelix vs leuprolide treatment in patients with advanced prostate cancer: PSA failures during a randomised, phase III trial (CS21). Eur Urol Suppl 2009 8 : 130